Trial Profile
A Single Dose, 4-way Crossover, Placebo-controlled, Randomized Study to Investigate the Effect of JNJ-42847922 on Polysomnography (PSG) Measures in Subjects With Major Depressive Disorder With Insomnia Who Are Stably Treated With Antidepressants
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Seltorexant (Primary)
- Indications Insomnia; Major depressive disorder
- Focus Pharmacodynamics
- Sponsors Janssen Research & Development
- 20 Sep 2016 Primary endpoint has been met. (Latency to Persistent Sleep (LPS) on Day 1)
- 20 Sep 2016 Results presented at the 29th Annual Congress of the European College of Neuropsychopharmacology
- 16 Jun 2015 Data from this study were presented by Janssen at the 29th annual meeting of the Associated Professional Sleep Societies, according to a Minerva Neurosciences media release.